Literature DB >> 20699382

Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis.

Gwenaëlle Abiven-Lepage1, Joël Coste, Frédérique Tissier, Lionel Groussin, Line Billaud, Bertrand Dousset, François Goffinet, Xavier Bertagna, Jérôme Bertherat, Marie-Laure Raffin-Sanson.   

Abstract

OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare, severe disease. Pregnancy-associated ACC has rarely been reported. We wished to evaluate the characteristics and prognosis of ACC diagnosed in patients during pregnancy or in the postpartum period, comparing them with those for ACC diagnosed in nonpregnant women.
DESIGN: Clinical presentation, hormonal secretion, staging, survival, and obstetric data are reported. Patients were included between 1963 and 2007. Mean follow-up was 48 months. PATIENTS AND METHODS: This is a retrospective cohort study carried out at a referral center. All female patients aged 16-49 years diagnosed with ACC during the observation period were included (n=110). Twelve of these women were pregnant or in the first 6 months after delivery. Hormonal secretion, staging, obstetric data, and survival were analyzed. For the survival analysis, pregnant patients were compared with a subgroup of nonpregnant women matched for age, stage, and year of diagnosis (1 pregnant patient/2 controls).
RESULTS: Adrenocortical tumors diagnosed during pregnancy or in the postpartum period tend to be more often cortisol-secreting tumors (P=0.06) and to be discovered at a more advanced stage than those in nonpregnant women, although the differences were not significant. Fetal outcome was poor. Overall survival of the mother was worse than that of matched controls (hazard ratio of death: 3.98, confidence interval=1.34-11.85, P=0.013).
CONCLUSION: ACC diagnosed during pregnancy or in the postpartum period is associated with a poor fetal outcome and a poorer prognosis than ACC diagnosed in nonpregnant women.

Entities:  

Mesh:

Year:  2010        PMID: 20699382     DOI: 10.1530/EJE-10-0412

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Adrenal cortical carcinoma mimicking early severe preeclampsia.

Authors:  Elizabeth Jarvis; Adam Morton
Journal:  Obstet Med       Date:  2013-10-29

2.  PKA signaling drives reticularis differentiation and sexually dimorphic adrenal cortex renewal.

Authors:  Typhanie Dumontet; Isabelle Sahut-Barnola; Amandine Septier; Nathanaëlle Montanier; Ingrid Plotton; Florence Roucher-Boulez; Véronique Ducros; Anne-Marie Lefrançois-Martinez; Jean-Christophe Pointud; Mohamad Zubair; Ken-Ichirou Morohashi; David T Breault; Pierre Val; Antoine Martinez
Journal:  JCI Insight       Date:  2018-01-25

Review 3.  Gestational Hyperandrogenism in Developmental Programming.

Authors:  Christopher Hakim; Vasantha Padmanabhan; Arpita K Vyas
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

4.  Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer.

Authors:  Elisa Rossini; Mariangela Tamburello; Andrea Abate; Silvia Beretta; Martina Fragni; Manuela Cominelli; Deborah Cosentini; Constanze Hantel; Federica Bono; Salvatore Grisanti; Pietro Luigi Poliani; Guido A M Tiberio; Maurizio Memo; Sandra Sigala; Alfredo Berruti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

Review 5.  The diagnosis and management of Cushing's syndrome in pregnancy.

Authors:  Ross Hamblin; Amy Coulden; Athanasios Fountas; Niki Karavitaki
Journal:  J Neuroendocrinol       Date:  2022-05-01       Impact factor: 3.870

6.  Adrenocortical carcinoma in pregnancy: A diagnostic dilemma.

Authors:  Ankush Jairath; Baldev S Aulakh
Journal:  Indian J Urol       Date:  2014-07

7.  The diagnosis and treatment of adrenocortical carcinoma in pregnancy: a case report.

Authors:  Yuanli Zhang; Zeng Yuan; Chunping Qiu; Shuyi Li; Shiqian Zhang; Yan Fang
Journal:  BMC Pregnancy Childbirth       Date:  2020-01-21       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.